Cancer immunotherapy gains acceptance; Alexza gets $15M loan; Bioengineering advances drug delivery;

> Mentor Capital has noted that with the featuring of Dendreon's Provenge prostate cancer vaccine on Fox News, cancer immunotherapy has come to a new point of popular acceptance. "One year ago only biotech investment reviews and medical journal reports followed pioneering cancer immunotherapy index member, Dendreon, as it climbed 1,000% in forty-five days." Mentor predicts other Dendreon-like companies in its "Cancer Immunotherapy Index (CII)" will also likely see a positive reaction. "Other CII companies are also pursuing treatments targeting cancer stem cells or brain, breast, melanoma and other cancer immunotherapies. Quite possibly, two or three markets of equal or greater size to Dendreon's will evolve, simply because there are two or three times the occurrence of cancer in the other cancer types that those companies are working on." Release

> Alexza Pharmaceuticals has executed a $15 million working capital loan agreement with Hercules Technology Growth Capital. Alexza's technology, the Staccato system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation. Alexza release

> In a keynote speech at the Association for Research in Vision and Ophthalmology meeting, Dr. Robert Langer said that advances in bioengineering will advance drug delivery and tissue regeneration. Report

> The past decade has seen a dramatic shift in terms of the types of approved injectable drugs, the diseases they target, and the devices used to deliver them, according to Greystone Associates. Report

Suggested Articles

Chiasma's new acromegaly pill Mycapssa, aiming to convert patients from injectables, turned out positive 48-week data from an extension study.

Medicated chewing gum is a prime drug delivery target, but it's tough to test. An experimental set of robot jaws could ease that burden.

J&J has new data that should convince regulators to clear its subcutaneous Darzalex in another indication—widening its edge over a Sanofi rival.